fbpx Skip to main content


Jeffrey Infante, M.D.



Jeffrey Infante, M.D. joined Janssen Research & Development in 2017 as Vice President, Oncology Early Development.

Prior to Janssen, Jeff was with the Sarah Cannon Research Institute in Nashville, Tennessee, where he worked as a clinical investigator and board-certified medical oncologist. During his tenure there, he served in many roles, including Director of the Drug Development Program. In this role, Jeff provided physician leadership to the Drug Development Unit in Nashville, which is one of the largest early phase clinical trial units for patients with advanced cancer in the country. He also provided physician oversight for other Sarah Cannon Phase 1 Drug Development Units in Florida, Oklahoma and Denver. He has helped design and conduct many clinical trials, ranging from first-in-human dosing through Phase 3 registration trials. He has expertise in the development of multiple novel treatments, including molecularly targeted therapies, antibody drug conjugates and immuno-oncology treatments.

Jeff received his undergraduate and medical degrees from the University of Florida and finished his Internal Medicine residency at Parkland Memorial Hospital, University of Texas Southwestern Medical Center. He completed his fellowship in Medical Oncology at Johns Hopkins University School of Medicine. Concurrent with his fellowship, he undertook formal training in patient-oriented research and received a Master of Health Science degree in Epidemiology at Johns Hopkins University’s Bloomberg School of Public Health. Additionally, for the past 10 years, he has been a practicing associate with Tennessee Oncology, PLLC.